A Prospective Observational Study on the Efficacy of Multiplex Genetic Analysis by Means of a Next-Generation Sequencer Using Cell-Free DNA
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000030496
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concordance of Guardant360 data for ctDNA and NGS data for tumor samples by Oncomine Comprehensive Assay (OCA)
- Secondary Outcome Measures
Name Time Method 1.The percentage of patients observed to have alterations to the 7 driver genes (EGFR, ALK, ROS1, BRAF, MET, RET, ERBB2). 2.Clinical efficacy (response rate, time to treatment failure, overall survival period) of molecular-targeted therapy in patients in whom genetic alterations are detected by Guardant360. 3.Time course of molecular profiling change which are related with drug resistance.